Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price
EPRXStock
$7.42+37.20%52W
Market Cap$490.26M
P/E—
PEG Ratio—
Div yield—
Beta1.23
EPRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.19%
Price vs S&P 500 (4W)11.94%
VGM Score46.81
EPRX Earnings Surprise History
Q2 25-0.26est. -0.18
Q3 25-0.19est. -0.19
Q4 25-0.37est. -0.16
Q2 26-0.23est. -0.23
EPRX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EPRXEupraxia Pharmaceuticals Inc. Common Stock | — | — | C | $7.42 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals is a clinical-stage biotech company developing extended-release, locally delivered therapeutics using its proprietary Diffusphere technology. Its lead candidate, EP-104, targets osteoarthritis and eosinophilic esophagitis, addressing unmet medical needs through improved drug delivery profiles.